News
Tectonic Therapeutic's lead drug candidate has yielded very encouraging results in early clinical studies. Find out why TECX ...
Mizuho initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $51 price target The company’s lead asset, TX45, is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback